Company Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease.
In addition, the company’s develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria.
Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Country | United States |
Founded | 2020 |
IPO Date | May 5, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 135 |
CEO | Mina Kim |
Contact Details
Address: 4149 Liberty Canyon Road Agoura Hills, California 91301 United States | |
Phone | 805-730-0360 |
Website | acelyrin.com |
Stock Details
Ticker Symbol | SLRN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $18.00 |
CIK Code | 0001962918 |
CUSIP Number | 00445A100 |
ISIN Number | US00445A1007 |
Employer ID | 85-2406735 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Mina Kim | Chief Executive Officer and Director |
Melanie Gloria B.S.N. | Chief Operating Officer |
Gilbert M. Labrucherie J.D. | Chief Financial Officer and Chief Business Officer |
Tyler Marciniak | Head of Investor Relations and Communications |
Sanam Pangali J.D. | Chief Legal Officer and Head of People |
Suzy Buckhalter CPA | Senior Director of Finance and Accounting |
Kenneth A. Lock | Chief Commercial Officer |
Dr. Shephard Mpofu M.D. | Chief Medical Officer |
Patricia A. Turney | Chief Technical Operations Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Aug 13, 2024 | 10-Q | Quarterly Report |
Aug 13, 2024 | 8-K | Current Report |
Aug 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jun 11, 2024 | 8-K | Current Report |
May 28, 2024 | 8-K/A | [Amend] Current report |
May 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
May 14, 2024 | 10-Q | Quarterly Report |
May 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
May 9, 2024 | 8-K | Current Report |